A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
Status:
Terminated
Trial end date:
2014-12-23
Target enrollment:
Participant gender:
Summary
This is an 11-week randomized, double-blind, placebo-controlled trial of Milnacipran 100 mg/d
in patients with idiopathic neuropathic pain. Milnacipran, a dual norepinephrine and
serotonin reuptake inhibitor has been a safe and beneficial treatment for patients with
fibromyalgia and may be useful to treat patients with painful peripheral neuropathy.
The primary outcome will be assessed by the change in daily averaged weekly 0-10 pain
intensity score, from baseline to week 9, by intention to treat analysis. The same analysis
will be used on several secondary measures including daily averaged weekly 0-10 pain
intensity score the sleep interference scale and the Rand-36 quality of life scale.